These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 22044248)

  • 1. Tau-targeted treatment strategies in Alzheimer's disease.
    Götz J; Ittner A; Ittner LM
    Br J Pharmacol; 2012 Mar; 165(5):1246-59. PubMed ID: 22044248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active full-length DNA Aβ
    Rosenberg RN; Fu M; Lambracht-Washington D
    Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau-based therapeutic approaches for Alzheimer's disease - a mini-review.
    Boutajangout A; Wisniewski T
    Gerontology; 2014; 60(5):381-5. PubMed ID: 24732638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapeutic approaches for Alzheimer's disease.
    Wisniewski T; Goñi F
    Neuron; 2015 Mar; 85(6):1162-76. PubMed ID: 25789753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau passive immunization inhibits not only tau but also Aβ pathology.
    Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches.
    Rüb U; Stratmann K; Heinsen H; Seidel K; Bouzrou M; Korf HW
    J Alzheimers Dis; 2017; 57(3):683-696. PubMed ID: 28269779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.
    Serrano-Pozo A; William CM; Ferrer I; Uro-Coste E; Delisle MB; Maurage CA; Hock C; Nitsch RM; Masliah E; Growdon JH; Frosch MP; Hyman BT
    Brain; 2010 May; 133(Pt 5):1312-27. PubMed ID: 20360050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau Biology and Tau-Directed Therapies for Alzheimer's Disease.
    Bakota L; Brandt R
    Drugs; 2016 Mar; 76(3):301-13. PubMed ID: 26729186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau immunotherapies for Alzheimer's disease.
    Hoskin JL; Sabbagh MN; Al-Hasan Y; Decourt B
    Expert Opin Investig Drugs; 2019 Jun; 28(6):545-554. PubMed ID: 31094578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer disease therapy--moving from amyloid-β to tau.
    Giacobini E; Gold G
    Nat Rev Neurol; 2013 Dec; 9(12):677-86. PubMed ID: 24217510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
    Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
    Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-amyloid-β Antibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives.
    Suzuki N; Hatta T; Ito M; Kusakabe KI
    Chem Pharm Bull (Tokyo); 2024; 72(7):602-609. PubMed ID: 38945936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Novel Therapeutic Strategies for Alzheimer's Disease].
    Tomita T
    Brain Nerve; 2024 Sep; 76(9):1053-1058. PubMed ID: 39251225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
    Kalra J; Khan A
    Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules.
    Davtyan H; Zagorski K; Rajapaksha H; Hovakimyan A; Davtyan A; Petrushina I; Kazarian K; Cribbs DH; Petrovsky N; Agadjanyan MG; Ghochikyan A
    Sci Rep; 2016 Jul; 6():28912. PubMed ID: 27363809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs for Targeted Therapies of Alzheimer's Disease.
    Tam C; Wong JH; Ng TB; Tsui SKW; Zuo T
    Curr Med Chem; 2019; 26(2):335-359. PubMed ID: 29714133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alzheimer disease: cellular and molecular aspects].
    Octave JN
    Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct Interaction between the β-Amyloid Core and Tau Facilitates Cross-Seeding: A Novel Target for Therapeutic Intervention.
    Tripathi T; Khan H
    Biochemistry; 2020 Feb; 59(4):341-342. PubMed ID: 31944100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.